Rezumat articol ediţie STUDIA UNIVERSITATIS BABEŞ-BOLYAI

În partea de jos este prezentat rezumatul articolului selectat. Pentru revenire la cuprinsul ediţiei din care face parte acest articol, se accesează linkul din titlu. Pentru vizualizarea tuturor articolelor din arhivă la care este autor/coautor unul din autorii de mai jos, se accesează linkul din numele autorului.

 
       
         
    STUDIA CHEMIA - Ediţia nr.3 din 2019  
         
  Articol:   LACK OF KINETIC INTERACTION BETWEEN ZOLPIDEM AND DULOXETINE: RESULTS FROM A DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEERS.

Autori:  ANA-MARIA GHELDIU, DANA MARIA MUNTEAN, MARIA NEAG, ADINA POPA, CORINA BRICIU, LAURIAN VLASE.
 
       
         
  Rezumat:   This open-label, non-randomized, two-period and sequential study aimed to evaluate a potential kinetic interaction between zolpidem ((N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide), a widely known and used sedative-hypnotic and duloxetine ((3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine), an antidepressant. A total of 23 healthy volunteers received the following medications: period 1 (Reference) - zolpidem 5 mg (single dose) and period 2 (Test) - zolpidem 5 mg and duloxetine 30 mg. Non-compartmental method was employed to determine the pharmacokinetic parameters of zolpidem and its main metabolite, zolpidem phenyl-4-carboxylic acid (Z4CA) while analysis of variance (ANOVA) was used to test the differences between study periods. Zolpidem exhibited similar pharmacokinetics with or without duloxetine (Cmax: 59.64±27.64 ng/mL vs 53.28±22.77 ng/mL, AUC0-t: 239.45±158.26 ng*h/mL vs 217.21±135.95 ng*h/mL, AUC0-∞: 245.87±161.84 ng*h/mL vs 224.61±138.86 ng*h/mL, t1/2: 2.97±2.06 vs 3.12±1.86 h). Subsequently, no marked changes were observed for Z4CA. The statistical test confirmed that duloxetine had no significant influence on the exposure to zolpidem and Z4CA (p<0.05 for all pharmacokinetic parameters). In conclusion, the study results excluded the possibility of a pharmacokinetic drug-drug interaction between these two drugs. Future investigations should focus on potential undesirable pharmacodynamic effects. Keywords: zolpidem, duloxetine, kinetic interaction, healthy volunteers  
         
     
         
         
      Revenire la pagina precedentă